Eric A. Hughes
Known title: See "Remarks"CIK: 0001938678
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▲ Buy | Option Exercise | 52,744 | — | 8/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 25,578 | $892K | 8/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 19,654 | — | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 9,533 | $302K | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 23,251 | — | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 11,277 | $366K | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 12,077 | $391K | 3/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 141,478 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 68,685 | $2.2M | 3/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 52,742 | — | 8/1/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 52,742 | $799K | 8/1/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 8,077 | $129K | 3/5/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 23,251 | — | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 15,174 | $239K | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 5,174 | $80K | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 19,726 | $319K | 3/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 45,060 | $783K | 8/9/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 52,742 | — | 8/1/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 24,537 | $423K | 8/1/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 8,045 | $107K | 3/4/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 52,742 | — | 8/1/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 52,742 | $438K | 8/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.